Accelerate Drug Development With Phase-Appropriate Thinking

By Ranjit Verma, Associate Director of Chemical Development

Drug development is filled with critical decisions, and making the wrong choice at the wrong stage can add unnecessary cost, complexity, and risk. A phase-appropriate approach helps teams focus on what is essential at each development milestone rather than investing time and resources in activities that may not yet deliver meaningful value.

From preclinical development through commercialization, priorities evolve significantly. Early decisions around regulatory strategy, process development, analytical methods, and GMP requirements should balance speed, flexibility, and future scalability. In many cases, pursuing the most sophisticated approach too early can create challenges later, limiting options and increasing development burdens. Conversely, underinvesting in key areas can slow progress when programs advance.

Successful development depends on understanding when to prioritize agility and when to build for long-term commercial readiness. Explore five practical considerations that can help development teams make informed, stage-appropriate decisions, reduce avoidable risks, and maintain momentum from discovery through market launch.